Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$4.05T | 39.4x | 0.42 | R$151.99 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$2.89T | 27.3x | R$80.14 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$1.84T | 88.3x | -70.6 | R$65 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.55T | 30.6x | 0.68 | R$167.54 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.46T | 16.2x | 2.02 | R$74.57 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.44T | 21.3x | 0.96 | R$77.04 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$937.71B | 24.2x | 0.28 | R$61.93 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$881.04B | 11x | 6.26 | R$25.47 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$866.32B | 20.4x | 0.01 | R$345.70 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$772.46B | 19.9x | -5.9 | R$34 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$590.22B | 16.6x | 0.09 | R$291.50 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$576.95B | 15.2x | 0.12 | R$57.96 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Vertex Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$561.03B | 28.9x | 0.03 | R$552.18 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| McKesson | B3 | Healthcare | Pharmaceuticals | R$527.16B | 24.8x | 0.41 | R$1,076.53 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron | B3 | Healthcare | Pharmaceuticals | R$387.10B | 18.1x | 2.1 | R$62.59 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$283.99B | 80.9x | -1.69 | R$93.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Zoetis | B3 | Healthcare | Pharmaceuticals | R$252.83B | 20.1x | 1.89 | R$37.69 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Cardinal Health | B3 | Healthcare | Pharmaceuticals | R$248.92B | 31x | 1.03 | R$1,054.08 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Alnylam Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$220.67B | 144.1x | 0.67 | R$84.24 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$184.61B | 25.9x | 0.14 | R$78.40 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$132.27B | 20.3x | -0.95 | R$148.95 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Moderna | B3 | Healthcare | Pharmaceuticals | R$107.41B | -7.5x | -0.34 | R$13.49 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Incyte | B3 | Healthcare | Pharmaceuticals | R$96.50B | 15.2x | 0 | R$242.64 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Biomarin | B3 | Healthcare | Pharmaceuticals | R$53.06B | 30.7x | -1.67 | R$139.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Hypera | B3 | Healthcare | Pharmaceuticals | R$14.80B | 12.4x | -1.17 | R$23.47 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | |
| Perrigo Company | B3 | Healthcare | Pharmaceuticals | R$7.88B | -1x | 0 | R$56.88 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.58B | 7.7x | 0.24 | R$11.52 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.5% Upside | Upgrade to Pro+ | |
| Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$1.70B | 7.7x | 0.11 | R$31.69 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18% Downside | Upgrade to Pro+ | |
| PROFARMA ON | B3 | Healthcare | Pharmaceuticals | R$1.02B | 8.3x | 2.25 | R$8.07 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$492.66M | 21.8x | 0.27 | R$1.62 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.8% Downside | Upgrade to Pro+ | |
| FII Nossa Senhora De Lourdes | B3 | Healthcare | Pharmaceuticals | R$242.49M | R$187.50 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |